Cargando…

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis

BACKGROUND: Ocrelizumab is a monoclonal antibody targeting CD20-expressing B cells used in the treatment of multiple sclerosis (MS). Currently, there is limited safety data in pregnancy. OBJECTIVES: To report the pregnancy outcome following exposure to ocrelizumab in MS. METHODS: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chey, Shin Yee, Kermode, Allan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905230/ https://www.ncbi.nlm.nih.gov/pubmed/35284087 http://dx.doi.org/10.1177/20552173221085737

Ejemplares similares

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor
por: Chey, Shin Yee, et al.
Publicado: (2022)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Viral pericarditis following ocrelizumab in a multiple sclerosis patient
por: Miele, Giuseppina, et al.
Publicado: (2023)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
por: Glanz, Bonnie I, et al.
Publicado: (2021)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
por: Neuberger, Edward E., et al.
Publicado: (2020)

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
por: Wolinsky, Jerry S, et al.
Publicado: (2020)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab
por: Landi, Doriana, et al.
Publicado: (2022)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
por: Fernandez‐Diaz, Eva, et al.
Publicado: (2020)

Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
por: Ho, Samantha, et al.
Publicado: (2023)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
por: Martins, Paulo, et al.
Publicado: (2022)

Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis
por: DEMİR, Caner Feyzi, et al.
Publicado: (2021)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study
por: Smoot, Kyle, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
por: ROJAS, Juan Ignacio, et al.
Publicado: (2021)

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review
por: Montalban, Xavier, et al.
Publicado: (2023)

No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS)
por: Kister, Ilya, et al.
Publicado: (2023)

Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe
por: Aun, Marcelo Vivolo, et al.
Publicado: (2022)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
por: Algahtani, Hussein, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v8nh2lcpc51hreng72a85cjevs